Trump/Cook, Nissan weakness, more tariffs and gold - what’s moving markets
On Monday, Citizens JMP analysts maintained their Market Outperform rating and $55.00 price target for Pharvaris B.V. (NASDAQ: PHVS) shares, representing significant upside from the current price of $15.90. According to InvestingPro data, analyst targets range from $13.82 to $54.94, with a consensus leaning strongly toward Buy. The firm’s analyst Jonathan Wolleben expressed continued confidence in the potential of deucrictibant, Pharvaris’s leading drug candidate.
Wolleben highlighted that while the latest data from open-label extensions in various settings did not reveal new information, it reinforced the drug’s promising profile. The analysis covered the acute, on-demand, and prophylactic use of deucrictibant, with all patients reporting quality of life improvements. These improvements were noted both quickly, within four weeks, and over a sustained period, up to 62 weeks. InvestingPro analysis shows the company maintains a strong financial position with a current ratio of 19.08, indicating robust liquidity to support ongoing drug development.
The analyst underscored the significance of the sustained positive impact on patients’ lives, suggesting that drugs which enhance patient well-being are more likely to be used consistently. Two key areas of improvement were identified: functioning and the reduction of fear/shame. These are considered critical benefits of an oral prophylactic treatment as opposed to injectable alternatives.
Further optimism was drawn from new data showing deucrictibant’s effectiveness in treating attacks that involve the upper airway. This finding is particularly notable as it supports the drug’s use as an oral treatment option for such attacks.
Pharvaris focuses on the development of novel therapies for hereditary angioedema and other bradykinin B2-receptor-mediated indications. The company’s commitment to advancing treatments for these conditions is reflected in the continued research and development of deucrictibant. With the maintained price target and rating, Citizens JMP’s stance indicates a positive outlook for Pharvaris’s stock performance moving forward. Trading near its 52-week low, the stock shows a unique beta of -3.08, suggesting it often moves counter to market trends. InvestingPro subscribers can access 8 additional key insights about Pharvaris’s financial health and market position.
In other recent news, Pharvaris B.V. has received notable attention from JMP Securities, which has adjusted the company’s price target to $55.00, up from a previous $46.00, while maintaining a Market Outperform rating. This adjustment comes amid Pharvaris’s progress in clinical trials for deucrictibant, a treatment for Hereditary Angioedema (HAE). The company is actively engaged in multiple studies, including the ongoing Phase 3 RAPIDe-3 trial, with top-line data expected in the first quarter of 2026. The analyst from JMP Securities, Jonathan Wolleben, emphasized the company’s unique position as the sole provider of an oral candidate for both prophylaxis and on-demand HAE treatment. Pharvaris’s extended-release version of deucrictibant is anticipated to capture a significant market share, supported by promising Phase 2 trial results. The updated price target reflects a revised revenue forecast and considers a larger addressable patient population. Wolleben’s analysis suggests that the potential market impact of Pharvaris’s product candidate could be substantial, contingent upon successful trial outcomes. These developments underscore the confidence in Pharvaris’s clinical strategy and future market potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.